Diamyd Medical (Sweden) Performance
| DMYD-B Stock | SEK 13.60 0.62 4.78% |
The firm shows a Beta (market volatility) of 1.23, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Diamyd Medical will likely underperform. At this point, Diamyd Medical AB has a negative expected return of -0.11%. Please make sure to confirm Diamyd Medical's coefficient of variation, jensen alpha, and the relationship between the mean deviation and standard deviation , to decide if Diamyd Medical AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Diamyd Medical AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest uncertain performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
| Begin Period Cash Flow | 139.4 M | |
| Total Cashflows From Investing Activities | -76.7 M |
Diamyd |
Diamyd Medical Relative Risk vs. Return Landscape
If you would invest 1,500 in Diamyd Medical AB on September 3, 2024 and sell it today you would lose (140.00) from holding Diamyd Medical AB or give up 9.33% of portfolio value over 90 days. Diamyd Medical AB is generating negative expected returns and assumes 2.7293% volatility on return distribution over the 90 days horizon. Simply put, 24% of stocks are less volatile than Diamyd, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Diamyd Medical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Diamyd Medical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Diamyd Medical AB, and traders can use it to determine the average amount a Diamyd Medical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0418
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | DMYD-B |
Estimated Market Risk
| 2.73 actual daily | 24 76% of assets are more volatile |
Expected Return
| -0.11 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Diamyd Medical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Diamyd Medical by adding Diamyd Medical to a well-diversified portfolio.
Diamyd Medical Fundamentals Growth
Diamyd Stock prices reflect investors' perceptions of the future prospects and financial health of Diamyd Medical, and Diamyd Medical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Diamyd Stock performance.
| Return On Equity | -0.42 | |||
| Return On Asset | -0.25 | |||
| Operating Margin | (170.83) % | |||
| Current Valuation | 1.06 B | |||
| Shares Outstanding | 76.93 M | |||
| Price To Earning | (4.21) X | |||
| Price To Book | 5.67 X | |||
| Price To Sales | 2,531 X | |||
| Revenue | 454 K | |||
| EBITDA | (98.88 M) | |||
| Cash And Equivalents | 119.76 M | |||
| Cash Per Share | 1.02 X | |||
| Book Value Per Share | 2.36 X | |||
| Cash Flow From Operations | (93.22 M) | |||
| Earnings Per Share | (1.45) X | |||
| Total Asset | 236.52 M | |||
| Retained Earnings | (31 M) | |||
| Current Asset | 33 M | |||
| Current Liabilities | 5 M | |||
About Diamyd Medical Performance
By analyzing Diamyd Medical's fundamental ratios, stakeholders can gain valuable insights into Diamyd Medical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Diamyd Medical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Diamyd Medical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Diamyd Medical AB , a diabetes company, engages in the development of combination therapies for the treatment of autoimmune diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB in April 2013. Diamyd Medical operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 6 people.Things to note about Diamyd Medical AB performance evaluation
Checking the ongoing alerts about Diamyd Medical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Diamyd Medical AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Diamyd Medical AB generated a negative expected return over the last 90 days | |
| The company reported the revenue of 454 K. Net Loss for the year was (118.18 M) with loss before overhead, payroll, taxes, and interest of (3.95 M). | |
| Diamyd Medical AB has accumulated about 119.76 M in cash with (93.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02. | |
| Roughly 35.0% of the company shares are held by company insiders |
- Analyzing Diamyd Medical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Diamyd Medical's stock is overvalued or undervalued compared to its peers.
- Examining Diamyd Medical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Diamyd Medical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Diamyd Medical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Diamyd Medical's stock. These opinions can provide insight into Diamyd Medical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Diamyd Stock analysis
When running Diamyd Medical's price analysis, check to measure Diamyd Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Diamyd Medical is operating at the current time. Most of Diamyd Medical's value examination focuses on studying past and present price action to predict the probability of Diamyd Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Diamyd Medical's price. Additionally, you may evaluate how the addition of Diamyd Medical to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |